Market focus Target long-segment peripheral artery disease treatment with minimally invasive endovascular solutions, aligning PQ Bypass growth opportunities with hospitals and vascular centers seeking innovative PAD therapies.

Strategic exits Leverage the acquisition by Endologix as a potential channel for partnerships or licensing opportunities, exploring co-development or distribution arrangements to accelerate market reach.

Clinical credibility Highlight FDA Breakthrough Device designation and prior CE mark approvals to prospective customers, illustrating regulatory readiness and robust clinical promise to reduce morbidity and mortality of invasive PAD procedures.

Executive access Engage with decision-makers who have backgrounds at Medtronic, Abbott, Johnson & Johnson, Covidien, and Stryker to facilitate enterprise-level discussions, procurement alignment, and large-system adoption.

Clinical data leverage Promote DETOUR trial milestones and subset analyses demonstrating low major adverse event rates, 30-day safety signals, and percutaneous bypass capabilities to support hospital credentialing and payer justification.